Compare GOGO & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GOGO | CCCC |
|---|---|---|
| Founded | 1991 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 461.2M | 404.7M |
| IPO Year | 2011 | 2020 |
| Metric | GOGO | CCCC |
|---|---|---|
| Price | $3.35 | $4.27 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $15.00 | $12.20 |
| AVG Volume (30 Days) | 2.4M | ★ 2.4M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.45 |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $910,491,000.00 | $35,947,000.00 |
| Revenue This Year | $3.68 | N/A |
| Revenue Next Year | $3.60 | N/A |
| P/E Ratio | $33.10 | ★ N/A |
| Revenue Growth | ★ 104.74 | 1.02 |
| 52 Week Low | $3.23 | $1.40 |
| 52 Week High | $16.82 | $4.60 |
| Indicator | GOGO | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 35.26 | 62.91 |
| Support Level | $3.29 | $2.10 |
| Resistance Level | $4.92 | $4.60 |
| Average True Range (ATR) | 0.27 | 0.37 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 10.81 | 77.88 |
Gogo Inc is a broadband connectivity service for the business aviation market. It provides a customizable suite of smart cabin systems for integrated connectivity, inflight entertainment, and voice solutions. It generates two types of revenue: service revenue consists of monthly subscription and usage fees paid by aircraft owners and operators for telecommunication, data, and in-flight entertainment services, and equipment revenue consists of proceeds from the sale of ATG and narrowband satellite connectivity equipment and is recognized when control of the equipment is transferred to OEMs and dealers, which generally occurs when the equipment is shipped. Geographically, it operates in United States; and International as well.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.